JOURNAL OF DRUG TARGETING

Scope & Guideline

Transforming drug targeting with cutting-edge research.

Introduction

Welcome to your portal for understanding JOURNAL OF DRUG TARGETING, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1061-186x
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1986 to 1987, from 1992 to 2024
AbbreviationJ DRUG TARGET / J. Drug Target.
Frequency10 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The 'Journal of Drug Targeting' aims to bridge the gap between drug development and clinical application, with a focus on innovative strategies for targeted drug delivery systems. The journal emphasizes the importance of nanotechnology, biomaterials, and precision medicine in enhancing therapeutic efficacy while minimizing side effects.
  1. Targeted Drug Delivery:
    Research focused on the development and optimization of drug delivery systems that enhance the targeting of therapeutic agents to specific tissues or cells, especially in cancer therapy.
  2. Nanotechnology Applications:
    Exploration of nanocarriers, nanoparticles, and nanomaterials for improving drug delivery, including the design and evaluation of systems that utilize their unique properties for targeted therapies.
  3. Biomaterials and Formulation Science:
    Investigations into the use of various biomaterials and formulations, including liposomes, micelles, and polymeric nanoparticles, to create effective and safe drug delivery systems.
  4. Molecular and Cellular Targeting Strategies:
    Studies on targeting specific molecular pathways, receptors, or antigens to enhance the efficacy of treatment while reducing adverse effects, particularly in the context of cancer and chronic diseases.
  5. Theranostics:
    Research that combines therapeutic and diagnostic approaches using nanotechnology to provide personalized medicine solutions, particularly in oncology.
The 'Journal of Drug Targeting' has seen a significant shift towards emerging themes that reflect the latest advancements in drug delivery technologies and therapeutic strategies. These trends highlight the journal's commitment to addressing contemporary challenges in drug targeting and therapy.
  1. Nanoparticle-Based Delivery Systems:
    The use of nanoparticles for drug delivery is rapidly gaining traction, with numerous studies exploring their potential to improve targeting accuracy, enhance drug stability, and reduce toxicity.
  2. Artificial Intelligence in Drug Design:
    The integration of artificial intelligence and machine learning in drug design and targeting strategies is becoming increasingly prominent, offering new avenues for personalized medicine and improved therapeutic outcomes.
  3. Immunotherapy and Targeting Cancer:
    Emerging research focuses on immunotherapeutic strategies that target specific immune pathways or cells, emphasizing the role of the immune system in combating cancer.
  4. Combination Therapies:
    There is a growing trend towards exploring combination therapies that leverage multiple mechanisms of action to enhance therapeutic efficacy and overcome resistance in cancer treatment.
  5. Green and Sustainable Nanotechnology:
    Increasing attention is being paid to environmentally friendly and sustainable approaches to nanotechnology in drug delivery, reflecting a broader trend towards responsible research practices.

Declining or Waning

While the journal maintains a strong focus on innovative drug targeting strategies, certain themes have shown signs of decline in prominence over recent years. These themes may reflect shifts in research priorities or advancements in technology that have made previous approaches less relevant.
  1. Traditional Chemotherapy:
    There appears to be a waning interest in conventional chemotherapy approaches, as research increasingly emphasizes targeted therapies and personalized medicine, which offer better efficacy and reduced side effects.
  2. Non-targeted Delivery Systems:
    Research on non-targeted or general drug delivery systems is becoming less frequent, as the focus shifts towards more sophisticated, targeted, and personalized delivery methods.
  3. Single-Drug Approaches:
    There is a noticeable decline in studies focusing solely on single-drug therapies without combination strategies, as multi-drug or combination therapies are increasingly favored for their enhanced effectiveness.

Similar Journals

Advanced NanoBiomed Research

Pioneering Research in Nanobiomedicine
Publisher: WILEY-V C H VERLAG GMBHISSN: 2699-9307Frequency: 12 issues/year

Advanced NanoBiomed Research is a pioneering open-access journal committed to advancing the interdisciplinary field of nanobiotechnology, published by WILEY-V C H VERLAG GMBH. Since its inception in 2021, this journal has provided a platform for innovative research that bridges the gap between engineering, medicine, and materials science. With impressive rankings in Scopus, positioning it within the top quartiles of various categories, Advanced NanoBiomed Research aims to disseminate high-quality research that contributes to the understanding and application of nanomaterials in biomedical contexts. As it encompasses a wide scope—from applied microbiology to biomaterials—it serves as an essential resource for researchers, professionals, and students eager to explore the cutting-edge developments in the field. The journal promotes a collaborative environment where emerging ideas can flourish, ensuring that vital advancements in nanobiomedicine can be shared and built upon within the scientific community.

Journal of Pharmaceutical Investigation

Exploring the forefront of pharmaceutical sciences for a healthier tomorrow.
Publisher: SPRINGERNATUREISSN: 2093-5552Frequency: 6 issues/year

Journal of Pharmaceutical Investigation, published by SPRINGERNATURE, is a leading academic resource in the field of pharmaceutical sciences, offering critical insights and innovative research findings. With an impact factor that underscores its significance, this journal ranks in the Q1 category for both Pharmacology and Pharmaceutical Science as of 2023, showcasing its high-quality publications and rigorous peer-review processes. Operating from the Netherlands, the journal spans from 2012 to 2024, offering a rich archive of interdisciplinary research contributions that advance knowledge in pharmacology, toxicology, and pharmaceutics. It holds impressive Scopus rankings, placing it among the top-tier journals in its categories, which enhances its appeal to researchers, professionals, and students aiming to publish their work or stay up-to-date with the latest advancements in the pharmaceutical field. Engaging with the Journal of Pharmaceutical Investigation not only enriches your understanding but also connects you with a community dedicated to advancing healthcare and therapeutic innovations.

International Journal of Pharmaceutics-X

Pioneering research at the forefront of pharmaceutical sciences.
Publisher: ELSEVIERISSN: Frequency: 1 issue/year

International Journal of Pharmaceutics-X is a premier open access journal published by Elsevier, dedicated to advancing knowledge and research in the field of pharmaceutical sciences. Launched in 2019, this journal has quickly ascended to the Q1 category in the 2023 Category Quartiles, reflecting its high impact and the quality of research it promotes. With a current Scopus ranking of #49 out of 183 in the Pharmacology, Toxicology and Pharmaceutics category, this journal occupies the 73rd percentile, showcasing its significant influence within the scholarly community. Emphasizing innovative research and novel applications, the International Journal of Pharmaceutics-X offers a platform for researchers, professionals, and students to disseminate their findings, making crucial contributions to the global pharmaceutical landscape. The journal is based in the Netherlands, presenting a vibrant hub for scientific discourse and collaboration in a rapidly evolving field.

International Journal of Nanomedicine

Connecting science and medicine through nanomedicine insights.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-2013Frequency: 1 issue/year

International Journal of Nanomedicine, published by DOVE MEDICAL PRESS LTD, is a leading open access journal dedicated to advancing the field of nanomedicine and its applications in healthcare. Since its establishment in 2006, the journal has grown significantly, now encompassing a wide array of topics including bioengineering, biomaterials, biophysics, drug discovery, and pharmaceutical sciences, and is recognized in Q1 quartiles across major categories like *Nanoscience and Nanotechnology* and *Organic Chemistry*. The journal boasts an impressive standing within the Scopus rankings, with high percentiles across various related fields, making it an invaluable resource for researchers, professionals, and students seeking to stay informed on the latest innovations and developments in nanomedicine. With its commitment to fostering an accessible and collaborative academic environment, the International Journal of Nanomedicine serves as a vital platform for disseminating transformative research that impacts scientific practice and healthcare outcomes globally.

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS

Elevating knowledge in therapeutic drug systems.
Publisher: BEGELL HOUSE INCISSN: 0743-4863Frequency: 6 issues/year

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS is an esteemed academic journal published by BEGELL HOUSE INC, focusing on the innovative field of drug delivery systems and therapeutic carriers. With an ISSN of 0743-4863 and E-ISSN 2162-660X, this journal serves as a pivotal resource for researchers, professionals, and students engaged in pharmaceutical sciences and pharmacology. Spanning from 1984 to 2024, it has sustained its relevance in an evolving landscape, holding a commendable Q2 ranking in both Medicine (miscellaneous) and Pharmaceutical Science, as well as a Q3 ranking in Pharmacology for 2023. The journal is well-regarded for its critical and comprehensive reviews that enhance understanding and drive advancements in therapeutic applications. Access options are variable, providing insights into contemporary practices and innovations that shape drug delivery strategies. With a strong emphasis on interdisciplinary approaches, CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS not only fosters scholarly dialogue but also propels forward the critical field of therapeutic delivery, making it a valuable asset for anyone looking to deepen their knowledge and influence within this dynamic area of study.

Discovery Medicine

Elevating the standards of discovery in medicine.
Publisher: DISCOVERY MEDICINEISSN: 1539-6509Frequency: 6 issues/year

Discovery Medicine, an esteemed journal published by Discovery Medicine, serves as a vital platform within the field of general medicine, dedicated to advancing knowledge through high-quality research and innovative insights. With its ISSN 1539-6509 and E-ISSN 1944-7930, this journal boasts an impressive Scopus ranking of #29 out of 529 in the general medicine category, positioning it at the 94th percentile, indicating its significant contribution to the medical sciences. While operating as a subscription-based journal, Discovery Medicine fosters an environment where researchers and professionals can disseminate their findings and engage with cutting-edge developments in medicine. Spanning topics that bridge clinical practice and healthcare advancements, this journal aims to inform, challenge, and inspire the medical community. The journal has converged its volumes from 2006 to 2007 and again from 2009 to 2018, highlighting its sustained commitment to excellence even as coverage has temporarily discontinued in Scopus. Situated at 10 Gerard Ave, Ste 201, Timonium, MD 21093, Discovery Medicine continues to be a cornerstone for medical scholars, offering a rich repository of knowledge essential for ongoing research and practical applications.

ADVANCED DRUG DELIVERY REVIEWS

Leading the Charge in Pharmaceutical Advancements.
Publisher: ELSEVIERISSN: 0169-409XFrequency: 12 issues/year

ADVANCED DRUG DELIVERY REVIEWS, published by ELSEVIER, is a leading journal in the field of pharmaceutical sciences, particularly acclaimed for its contributions to the disciplines of pharmacology, toxicology, and pharmaceutics. With an impressive 2023 Scopus rank of #1 out of 183 in its category, this journal is situated in the Q1 quartile, reflecting its high impact and the relevance of its published research. Since its inception in 1987, it has continually focused on the latest advancements in drug delivery systems, making it an indispensable resource for researchers, professionals, and students interested in the innovative developments that shape the pharmaceutical landscape. The journal aims to publish comprehensive and authoritative reviews that foster a deeper understanding of drug delivery mechanisms, technologies, and their clinical applications. Although it operates under a subscription model, the value it provides through rigorous peer-reviewed content ensures it remains an essential tool for anyone seeking to enhance their knowledge in this rapidly evolving field.

Advanced Pharmaceutical Bulletin

Advancing the Frontiers of Pharmaceutical Science
Publisher: TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICESISSN: 2228-5881Frequency: 2 issues/year

Advanced Pharmaceutical Bulletin, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, serves as a pivotal platform for disseminating groundbreaking research in the field of pharmaceutical sciences. Since its inception in 2011, this open-access journal has dedicated itself to advancing knowledge in pharmacology, toxicology, and pharmaceutics, boasting an impressive Q1 ranking in miscellaneous categories and Q2 in pharmaceutical science as of 2023. The journal is noted for its rigorous peer-review process, ensuring that published work meets the highest standards of scientific inquiry. With notable rankings, including 7th out of 80 in general pharmacology and toxicology, it sits in the 91st percentile, highlighting its significance in the research community. Researchers and practitioners alike can access cutting-edge findings and innovative methodologies, promoting collaboration and knowledge within the scientific community. Based in Tabriz, Iran, the journal remains committed to fostering research excellence, making it an invaluable resource for scholars and professionals eager to contribute to the dynamic field of pharmaceuticals.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY

Innovative Insights for Enhanced Drug Formulation and Safety.
Publisher: TAYLOR & FRANCIS LTDISSN: 1083-7450Frequency: 6 issues/year

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY is a premier journal published by Taylor & Francis Ltd that focuses on the latest advancements and innovations in the field of pharmaceutical science. Established in 1996, this journal has evolved to encompass a wide array of interdisciplinary studies relevant to drug development, formulation technology, and delivery systems, serving as a platform for researchers and professionals to share groundbreaking findings. With an impressive impact factor and ranked in both Q2 in Pharmaceutical Science and Q3 in Medicine (miscellaneous), it positions itself among the top-tier journals in pharmacology and toxicology. The journal's insights are critical for scholars and practitioners aiming to enhance therapeutic efficacy and safety. Access options for the content remain traditional, thus supporting a comprehensive approach to scientific literature. Throughout its converged years up to 2024, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY continues to play a vital role in shaping pharmaceutical education and practice.

International Journal of Pharmaceutics

Connecting researchers to revolutionize pharmaceutical practices.
Publisher: ELSEVIERISSN: 0378-5173Frequency: 21 issues/year

The International Journal of Pharmaceutics, a prestigious publication from ELSEVIER, stands at the forefront of the pharmaceutical science field, exemplified by its impressive ranking of #15 out of 183 in Pharmacology, Toxicology, and Pharmaceutics, placing it in the 92nd percentile. Established in 1978, this journal has continuously provided a platform for researchers, professionals, and students to share groundbreaking discoveries and innovations in drug formulation, delivery systems, and pharmacokinetics. With a Q1 ranking in the 2023 category of Pharmaceutical Science, it underscores its significance in disseminating high-quality research that shapes clinical practices and enhances therapeutic outcomes. While the journal does not currently offer open access options, it remains accessible to subscribers through its publication based in Amsterdam, Netherlands, ensuring a broad reach within the scientific community. As it converges towards a vibrant future, the International Journal of Pharmaceutics continues to be an essential resource for anyone dedicated to advancing the field of pharmacy and drug development.